Table 1.
Baseline demographics and disease characteristics
| n = 62 | |
|---|---|
| Age (y), median (range) | 36 (18–69) |
| Sex, n (%) | |
| Male | 30 (48) |
| Female | 32 (52) |
| Disease stage at initial diagnosis, n (%) | |
| I/II | 37 (60) |
| III/IV | 24 (39) |
| Unknown | 1 (2) |
| Prior systemic therapy regimens, n (%) | |
| ABVD | 56 (90) |
| ABVE-PC | 2 (3) |
| R-ABVD | 1 (2) |
| BEACOPP* | 2 (3) |
| Stanford V | 2 (3) |
| Prior radiation therapy, n (%) | 9 (15) |
| Disease status relative to frontline treatment, n (%) | |
| Primary refractory | 28 (45) |
| PR or SD to frontline therapy | 10 (16) |
| PD to frontline therapy | 18 (29) |
| Relapsed | 34 (55) |
| Remission duration ≤1 y | 19 (31) |
| Remission duration >1 y | 15 (24) |
| Time (mo) from end of frontline therapy to relapse, median (range) | 9.1 (2.3–90.7) |
| ECOG performance status, n (%) | |
| Grade 0 | 39 (63) |
| Grade 1 | 23 (37) |
| Bulky disease at baseline, n (%) | 8 (13) |
| Extranodal disease at baseline, n (%) | 16 (26) |
ABVD, Adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine; ABVE-PC, Adriamycin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; BEACOPP, bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphamide, Oncovin (vincristine), procarbazine, and prednisone; R-ABVD, rituximab-supplemented ABVD; SD, stable disease.
*
One patient received BEACOPP after discontinuing ABVD because of inadequate interim response.